Study guide
1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi
Board Certified Infectious Diseases Pharmacist BCIDP
Track your progress as you read
Finished sections get a check mark.
1 Causes of Infectious Diseases
1.1 Bacterial Pathogens: Gram-Positive, Gram-Negative, and Atypical Organisms 1.2 Viral Pathogens: Respiratory, Herpesviruses, Hepatitis, and Emerging Viruses 1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi 1.4 Parasitic and Vector-Borne Pathogens: Protozoa and Helminths
2 Microbiology Diagnostics, Resistance & Host Response
2.1 Diagnostic Microbiology: Phenotypic, Molecular, and Rapid Diagnostic Methods 2.2 Molecular Mechanisms of Antimicrobial Resistance 2.3 Microbial Virulence Factors, Toxins, and Biofilm Dynamics 2.4 Host Immune Response to Infection and Immunopathology
3 Clinical Assessment & Diagnostic Evaluation
3.1 Clinical Assessment, Infection Screening, and Severity Stratification 3.2 Diagnostic Biomarkers and Clinical Laboratory Interpretation 3.3 Social Determinants of Health and Disparities in Infectious Diseases
4 Pharmacokinetics, Pharmacodynamics & Special Populations
4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials 4.2 Host and Environmental Risk Factors for Infection 4.3 Antimicrobial Dosing and Considerations in Special Populations
5 Respiratory and Skin/Soft Tissue Infections
5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections 5.2 Pharmacotherapy of Skin and Soft Tissue Infections
6 Cardiovascular, Bone, and Joint Infections
6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections 6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI
7 Central Nervous System and Abdominal Infections
7.1 Pharmacotherapy of Central Nervous System Infections 7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections
8 Urologic, Gynecologic, and Sexually Transmitted Infections
8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections 8.2 Pharmacotherapy of Sexually Transmitted Infections
9 HIV Infection and Opportunistic Infections
9.1 Antiretroviral Therapy and Management of HIV-1 Infection 9.2 Prophylaxis and Management of HIV-Associated Opportunistic Infections
10 Infections in Immunocompromised Hosts and Complex Syndromes
10.1 Infections in Solid Organ Transplant and Hematologic Malignancy 10.2 Sepsis, Septic Shock, and Systemic Complications
11 Medication Administration and Adjunctive Therapies
11.1 Antimicrobial Administration, Vascular Access, and Stability 11.2 Adjunctive Pharmacotherapies and Supportive Care in Serious Infections 11.3 Assessment of Therapeutic Outcomes and Infection Failure
12 Therapeutic Drug Monitoring, Toxicity, and De-escalation
12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics 12.2 Antimicrobial Adverse Drug Events and High-Risk Drug Interactions 12.3 Antimicrobial De-escalation and IV-to-Oral Transition Strategies
13 Care Transitions, Patient Counseling & Travel Medicine
13.1 Outpatient Parenteral and Complex Oral Antimicrobial Therapy (OPAT/COPAT) 13.2 Patient and Caregiver Counseling, Education, and Adherence 13.3 Travel Medicine, Immunizations, and Prophylactic Regimens
14 Antimicrobial Stewardship Operations, Metrics & Resistance
14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates 14.2 Stewardship Metrics: Days of Therapy (DOT), DDD, and SAAR 14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns 14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis
15 Formulary Management, Infection Prevention & Population Health
15.1 Antimicrobial Formulary Management and Restriction Strategies 15.2 Public Health, Disease Reporting, and Adult Immunization Strategies 15.3 Healthcare Infection Prevention and Environmental Transmission
16 Literature Evaluation, Informatics & Quality Improvement
16.1 Infectious Diseases Information Resources, Databases, and Clinical Guidelines 16.2 Critical Literature Evaluation and Biostatistical Interpretation 16.3 Quality Improvement Methodologies and Medication Safety in ID 16.4 Clinical Informatics, Decision Support Systems, and Automated Alerts
1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi
Key Takeaways Explain This Topic AI
Candida glabrata displays dose-dependent susceptibility or resistance to fluconazole via PDR1 transcription factor upregulation of efflux pumps and develops echinocandin resistance via FKS1/FKS2 hotspot mutations, while Candida krusei is intrinsically fluconazole-resistant due to low-affinity ERG11.
Candida auris presents a global infection control crisis due to multidrug resistance across azoles, polyenes, and echinocandins, prolonged environmental persistence, and misidentification by conventional biochemical systems.
Invasive aspergillosis features acute-angle (45°) dichotomous branching septate hyphae and galactomannan antigen positivity, whereas Mucorales demonstrate broad, ribbon-like, pauciseptate hyphae branching at right angles (90°) that are intrinsically resistant to voriconazole.
Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides species are thermal dimorphic fungi that transition from environmental mycelial molds to pathogenic yeasts or spherules at 37°C within human host tissues.
Pneumocystis jirovecii trophic forms lack cell wall ergosterol, conferring intrinsic resistance to azoles, polyenes, and echinocandins, while containing (1,3)-beta-D-glucan in cyst forms, which serves as a valuable diagnostic biomarker.
Last updated: October 2026
Fungal Cell Architecture, Diagnostic Biomarkers, and Classification
Fungi are eukaryotic heterotrophs encased in a complex, rigid cell wall distinct from bacterial peptidoglycan and mammalian plasma membranes. Understanding the fungal cell envelope is essential for clinical diagnostic interpretation and pharmacotherapeutic stewardship: FUNGAL CELL ENVELOPE ARCHITECTURE
- EXTRACELLULAR SPACE
- ─────────────────────────────────────────────────────────────────────────────
- Outer Layer: Mannoproteins (Serologic & antigenic determinants)
- ────────────────────────────────────────────────────────────
- Middle Layer: (1,3)-beta-D-Glucan & (1,6)-beta-D-Glucan (Structural matrix)
- [Target of Echinocandins: Caspofungin, Micafungin, Anidulafungin]
- [Biomarker: Fungitell Serum Assay]
- ────────────────────────────────────────────────────────────
- Inner Layer: Chitin (N-acetylglucosamine polymer, tensile strength)
- ─────────────────────────────────────────────────────────────────────────────
- Plasma Membrane: Ergosterol (Fungal sterol maintaining membrane fluidity)
- [Target of Polyenes: Amphotericin B, Nystatin (Binds ergosterol)]
- [Target of Azoles: Inhibits 14-alpha-demethylase (ERG11 / cyp51A)]
- [Target of Allylamines: Terbinafine (Inhibits squalene epoxidase)]
- ─────────────────────────────────────────────────────────────────────────────
- CYTOPLASM
- Serological and Antigenic Biomarkers
Non-culture-based diagnostics provide rapid diagnostic insights, though each biomarker carries distinct microbiological scope and limitations:
(1,3)-beta-D-Glucan (BDG / Fungitell): A major structural cell-wall component shed continuously during active fungal growth. BDG detects a broad spectrum of invasive fungal pathogens, including Candida species , Aspergillus species , Pneumocystis jirovecii , and Fusarium . However, BDG has critical diagnostic blind spots:
Negative or Low Sensitivity: Completely lacks or demonstrates negligible BDG in the cell walls of Mucorales (which contain chitin and chitosan instead of glucan) and Cryptococcus species (where a thick glucuronoxylomannan capsule masks glucan release). It also displays variable sensitivity in Blastomyces .
False-Positive Triggers: Cellulose hemodialysis filters, exposure to surgical gauze/sponges, intravenous immunoglobulin (IVIG), human albumin, severe Gram-negative bacteremia, and historical formulations of beta-lactamase inhibitor antibiotics (e.g., piperacillin-tazobactam).
Galactomannan (GM / Platelia): A heat-stable heteropolysaccharide constituent of the cell wall of Aspergillus species , released during active tissue invasion. Tested in serum and bronchoalveolar lavage (BAL) fluid. BAL galactomannan exhibits superior diagnostic sensitivity (>85–90%) compared to serum, particularly in non-neutropenic patients where circulating antibody complexes rapidly clear serum antigen. False-positive galactomannan results occur with cross-reacting fungal pathogens ( Fusarium , Histoplasma , Blastomyces , Talaromyces ) and gluconate-containing intravenous hydration fluids (e.g., Plasmalyte).
Cryptococcal Antigen (CrAg): Detects the glucuronoxylomannan (GXM) capsular polysaccharide of Cryptococcus neoformans and Cryptococcus gattii via lateral flow assay (LFA) or latex agglutination in serum and CSF. The lateral flow assay demonstrates exceptional sensitivity and specificity (>98–99%), providing rapid diagnosis of cryptococcal meningoencephalitis.
- Pathogenic Yeasts: Candida and Cryptococcus Species
- The Genus Candida
Candida species are ubiquitous commensals of the human gastrointestinal tract, female genitourinary tract, and cutaneous folds. Disruption of mucosal integrity (chemotherapy-induced mucositis, gastrointestinal surgery), indwelling vascular catheters, broad-spectrum antibiotics, or neutropenia permits hematogenous invasion, leading to candidemia and deep-seated invasive candidiasis.
Species Baseline Azole Profile Echinocandin Activity Key Molecular Resistance Determinants & Clinical Features
Candida albicans Highly Susceptible Highly Susceptible Most common isolate; germ tube positive; forms true hyphae and pseudohyphae; resistance occurs via ERG11 mutations or CDR1/MDR1 efflux
Candida glabrata Susceptible-Dose Dependent (SDD) or Resistant Susceptible (Acquired resistance emerging) Haploid yeast; non-dimorphic; PDR1 gain-of-function mutations upregulate CDR1/CDR2 efflux; echinocandin resistance via FKS1/FKS2 hotspot mutations
Candida krusei Intrinsically Resistant to Fluconazole Highly Susceptible Expresses altered ERG11 with low fluconazole binding affinity; remains susceptible to voriconazole, isavuconazole, and echinocandins
Candida parapsilosis Typically Susceptible Naturally Elevated MICs Major colonizer of hands, IV lines, prosthetic devices; naturally carries FKS1 P660A polymorphism; clonal azole resistance ( ERG11 Y132F) emerging
Candida auris Highly Resistant (>90%) Variable Resistance (5–10%) Global multidrug-resistant threat; persists on hospital surfaces; requires contact precautions; misidentified on older automated phenotypic systems
Important
Clinical and Laboratory Standards Institute (CLSI) removed the "susceptible" breakpoint for fluconazole against Candida glabrata , designating all wild-type isolates as Susceptible-Dose Dependent (SDD) (MIC ≤ 32 mg/L) or Resistant (MIC ≥ 64 mg/L). SDD isolates require high-dose fluconazole (800 mg/day or 12 mg/kg/day in adults with normal renal clearance) to achieve target pharmacodynamic A U C / M I C AUC/MIC A U C / M I C ratios. Resistance in C. glabrata is driven by point mutations in the PDR1 transcription factor, triggering constitutive overexpression of ATP-binding cassette (ABC) transporter efflux pumps ( Cdr1 , Cdr2 , Snq2 ). ECHINOCANDIN RESISTANCE MECHANISM
Wild-Type Fungal Membrane: Echinocandin-Resistant Mutant:
- ───────────────────────── ──────────────────────────────
- Fks1p / Fks2p Catalytic Subunit Fks1p / Fks2p Amino Acid Substitution
- [Conserved Hotspot 1 & 2 Regions] [e.g., Fks1 S645P or Fks2 S663P]
- │ │
- ▼ ▼
- Echinocandin binds with high affinity Steric hindrance prevents echinocandin binding
- │ │
- ▼ ▼
- Beta-(1,3)-glucan synthesis inhibited Beta-(1,3)-glucan synthesis continues intact
- [Osmotic lysis & cell death] [Elevated MICs & Clinical Failure]
Acquired echinocandin resistance in Candida is mediated by non-synonymous point mutations in conserved "hotspot" regions (Hotspot 1 and Hotspot 2) of the FKS1 gene (and FKS2 in C. glabrata ), which encode the catalytic subunits of (1,3)-beta-D-glucan synthase. These substitutions (e.g., Fks1 S645P in C. albicans ; Fks2 S663P in C. glabrata ) cause steric hindrance that decreases drug-target binding affinity, producing marked clinical treatment failures.
Candida auris Public Health Threat: C. auris presents three unprecedented challenges: (1) Multidrug resistance , with >90% resistance to fluconazole, up to 30% resistance to amphotericin B, and 5–10% resistance to echinocandins (with pan-resistant isolates documented); (2) Healthcare environmental persistence , shedding from human skin (axilla, groin) and persisting for months on inanimate surfaces and medical equipment, causing refractory hospital outbreaks; (3) Diagnostic misidentification , frequently misidentified by older automated biochemical systems (e.g., VITEK 2, API 20C AUX) as Candida haemulonii , Candida famata , or Rhodotorula , requiring MALDI-TOF mass spectrometry or molecular DNA sequencing for accurate confirmation.
The Genus Cryptococcus
Cryptococcus neoformans (predominantly var. grubii ) and Cryptococcus gattii are encapsulated basidiomycetous yeasts. C. neoformans is ubiquitous in avian guano (pigeons) and decaying soil, causing opportunistic central nervous system disease in hosts with defective cell-mediated immunity (advanced HIV with CD4 <100 cells/ μ \mu μ L, solid organ transplant recipients, and patients on fingolimod or high-dose corticosteroids). C. gattii is associated with eucalyptus trees and native soil in tropical, subtropical, and temperate regions (Pacific Northwest), characteristically causing invasive pulmonary cryptococcomas and cerebral lesions in immunocompetent hosts.
Morphology: Round-to-oval yeasts (4–10 μ \mu μ m) surrounded by a prominent, wide mucopolysaccharide capsule composed of glucuronoxylomannan (GXM) that excludes India ink particles under light microscopy. The yeast produces melanin via the laccase enzyme, conferring protection against host oxidative killing.
Cryptococcal Meningoencephalitis: Inhaled basidiospores or desiccated yeasts germinate in pulmonary alveoli, followed by hematogenous dissemination and neurotropism (traversing the blood-brain barrier via transcellular migration or "Trojan horse" macrophage carriage). Manifests as subacute headache, fever, cranial neuropathies, and dangerously elevated intracranial opening pressure ( > 200 mm H 2 O >200\text{ mm H}_2\text{O} > 200 mm H 2 O in > 50 % >50\% > 50% of patients). Induction therapy requires combination liposomal amphotericin B plus oral flucytosine (5-FC) for at least two weeks, followed by consolidation and maintenance fluconazole, coupled with therapeutic serial lumbar punctures to relieve intracranial hypertension.
Pathogenic Molds: Aspergillus, Mucorales, and Other Opportunistic Molds DIAGNOSTIC DIFFERENTIATION OF INVASIVE MOLDS
- ASPERGILLUS SPECIES MUCORALES
- ──────────────────────────────────────── ────────────────────────────────────────
- Hyphae: Thin, uniform (3-5 µm) • Hyphae: Broad, ribbon-like (6-25 µm)
- Septation: Regularly septate • Septation: Pauciseptate or aseptate
- Branching: Acute angle (dichotomous 45°) • Branching: Wide angle (variable 90°)
- Biomarkers: Galactomannan (+), BDG (+) • Biomarkers: Galactomannan (-), BDG (-)
- Primary Therapy: Voriconazole / Isavu. • Primary Therapy: Emergent Surgery +
- Ampho B Activity: Susceptible (except High-Dose Liposomal Ampho B / Isavu.
- A. terreus, which is intrinsically • Voriconazole Activity: ZERO ACTIVITY
- resistant to Amphotericin B!) (Risk of breakthrough infection!)
- Aspergillus Species
Aspergillus species ( A. fumigatus , A. flavus , A. terreus , A. niger ) are ubiquitous environmental saprophytic molds producing millions of airborne conidia (spores) that are inhaled into the respiratory tract. In severely immunocompromised patients (prolonged absolute neutrophil count <500 cells/ μ \mu μ L, allogeneic HCT with graft-versus-host disease [GVHD], high-dose corticosteroids, or severe viral pneumonitis [influenza/COVID-19 associated pulmonary aspergillosis]), conidia germinate into septate hyphae that invade blood vessels.
Clinical Presentation: Invasive Pulmonary Aspergillosis (IPA) presents with pleuritic chest pain, fever, hemoptysis, and cavitary nodules. Thoracic CT demonstrates the halo sign (a nodular consolidation surrounded by a rim of ground-glass attenuation representing perilesional alveolar hemorrhage) which evolves into an air crescent sign upon neutrophil recovery.
Species-Specific Nuances:
Aspergillus terreus : INTRINSICALLY RESISTANT TO AMPHOTERICIN B! Voriconazole or isavuconazole is the mandatory treatment of choice.
Triazole-Resistant A. fumigatus : Emerging globally secondary to environmental agricultural spraying of sterol demethylation inhibitor (DMI) triazole fungicides. Driven by tandem repeat insertions in the cyp51A promoter coupled with amino acid substitutions (e.g., T R 34 / L 98 H TR_{34}/L98H T R 34 / L 98 H and T R 46 / Y 121 F / T 289 A TR_{46}/Y121F/T289A T R 46 / Y 121 F / T 289 A ), resulting in cross-resistance to medical triazoles.
The Mucorales (Zygomycetes)
The order Mucorales encompasses aggressive environmental molds of the genera Rhizopus (most prevalent), Mucor , Lichtheimia (formerly Absidia ), Rhizomucor , and Cunninghamella .
Pathophysiology: Mucorales possess specialized surface protein adhesins (CotH invasins) that bind to glucose-regulated protein 78 (GRP78) on host endothelial cells, triggering rapid endocytosis, extensive vascular invasion, catastrophic thrombosis, and extensive tissue necrosis (eschar formation).
High-Risk Hosts:
Diabetic Ketoacidosis (DKA): Hyperglycemia and acidemia dissociate iron from transferrin; free serum iron is scavenged by fungal high-affinity iron permeases, accelerating fungal proliferation. This drives rhino-orbital-cerebral mucormycosis , presenting with facial pain, proptosis, ophthalmoplegia, and black necrotic eschars on the hard palate or nasal turbinates.
Severe Neutropenia and Corticosteroids: Promotes angioinvasive pulmonary mucormycosis. Thoracic CT characteristically demonstrates the reverse halo sign (a central area of ground-glass attenuation surrounded by a dense ring of consolidation).
Iron Overload & Deferoxamine Therapy: Deferoxamine acts as a fungal siderophore (ferrioxamine), donating iron directly to Rhizopus .
Warning
VORICONAZOLE HAS ZERO ACTIVITY AGAINST THE MUCORALES. Breakthrough mucormycosis is a well-documented complication in leukemia and transplant patients receiving voriconazole prophylaxis for aspergillosis. Successful treatment mandates an emergent dual strategy: immediate radical surgical debridement of necrotic tissues combined with high-dose intravenous liposomal amphotericin B (5–10 mg/kg/day) or isavuconazole / posaconazole .
Other Opportunistic Filamentous Molds
Fusarium Species ( F. solani , F. oxysporum ): Hyaline molds with sickle-shaped (banana-like) multicellular macroconidia. Causes locally invasive keratitis (contact lenses) and disseminated disease in neutropenic patients. Unlike Aspergillus , Fusarium produces positive blood cultures in >50% of disseminated cases due to adventitious sporulation within the vascular tree, accompanied by disseminated, painful, necrotic cutaneous target lesions. Highly resistant in vitro to multiple antifungals.
Scedosporium apiospermum Complex ( Pseudallescheria boydii ): Septate mold that is intrinsically resistant to amphotericin B ; voriconazole is the established agent of choice.
Lomentospora prolificans (formerly Scedosporium prolificans ): Dematiaceous (melanized) mold that exhibits pan-antifungal resistance to polyenes, echinocandins, and azoles. Associated with near 100% mortality in disseminated infections; experimental synergy regimens (e.g., voriconazole plus terbinafine plus miltefosine) and surgical resection are required.
- Endemic Dimorphic Fungi and Pneumocystis jirovecii
- Thermal Dimorphic Fungi
Endemic dimorphic fungi exhibit a distinct thermal dimorphism that serves as their primary survival and virulence adaptation:
Environmental Saprophytic Phase (25°C–30°C): Exists as branching hyphal mycelia in soil, producing infectious microconidia, macroconidia, or arthroconidia that become airborne when soil is disturbed.
Host Parasitic Phase (37°C): Inhalation into warm human alveoli triggers rapid morphological transition into pathogenic yeasts (or endospore-filled spherules), upregulating cell-wall alpha-(1,3)-glucans that mask immunostimulatory beta-glucans and permit survival within host phagocytes.
Pathogen Geographic Distribution Environmental Reservoir Tissue Morphology at 37°C Hallmark Clinical Manifestations
Histoplasma capsulatum Ohio & Mississippi River valleys, Central/South America Bird/bat guano, caves, chicken coops, demolition Small, narrow-based budding oval yeasts (2–4 μ \mu μ m) inside macrophages Reticuloendothelial invasion, hepatosplenomegaly, adrenal crisis, pancytopenia
Blastomyces dermatitidis Great Lakes, Ohio/Mississippi basins, St. Lawrence Decaying wood, moist acidic soil, riverbanks Large, spherical, thick-walled yeasts (8–15 μ \mu μ m) with broad-based budding Primary lung infiltrates, verrucous/ulcerative skin lesions, osteomyelitis
Coccidioides immitis / posadasii Arid desert southwest (San Joaquin Valley, Arizona) Alkaline desert soil, dust storms, construction Thick-walled spherules (20–100 μ \mu μ m) filled with endospores (2–5 μ \mu μ m) Valley fever, erythema nodosum, osteolytic lesions, chronic basilar meningitis
Paracoccidioides brasiliensis Central and South America (Brazil, Colombia) Humid agricultural soil, coffee/tobacco farming Large parent yeast surrounded by multiple buds ( "mariner's wheel" ) Chronic mucosal ulcerative lesions of oropharynx, cervical lymphadenopathy
Talaromyces marneffei Southeast Asia (Thailand, Vietnam, southern China) Bamboo rats, agricultural soil Intracellular yeast that divides by binary fission with a central transverse septum Umbilicated facial papules with central necrotic crusts in advanced HIV
Histoplasma capsulatum : Intracellular yeast with affinity for the reticuloendothelial system. Progressive disseminated histoplasmosis (PDH) occurs in patients with advanced HIV (CD4 <150 cells/ μ \mu μ L) or solid organ transplantation, presenting with fevers, weight loss, hepatosplenomegaly, diffuse lymphadenopathy, pancytopenia, oral mucosal ulcers, and bilateral adrenal enlargement risking adrenal insufficiency. The urine and serum Histoplasma galactomannan antigen provides rapid sensitivity (>90% in disseminated disease), though it cross-reacts with Blastomyces and Paracoccidioides .
Blastomyces dermatitidis : Demonstrates a thick, doubly refractile cell wall and pathognomonic broad-based budding (where the daughter bud shares a wide junction with the parent cell before detachment). Dissemination occurs in up to 40–50% of patients, frequently involving the skin (verrucous, crusted hyperkeratotic lesions mimicking squamous cell carcinoma), bone (osteomyelitis of long bones and vertebrae), and the male genitourinary tract (prostatitis, epididymitis).
Coccidioides immitis and posadasii : Inhaled barrel-shaped arthroconidia enlarge in alveoli to form massive spherules filled with hundreds of endospores; rupture releases endospores that propagate infection. In addition to acute "Valley Fever" (fever, arthralgias, and erythema nodosum), dissemination can involve bones, joints, and the central nervous system ( coccidioidal meningitis ). Complement fixation (CF) titers correlate directly with disease severity; a serum CF titer ≥ 1:16 strongly suggests extrapulmonary dissemination, while CF antibodies in CSF confirm meningitis, requiring lifelong daily fluconazole (400–1,200 mg/day) to prevent fatal relapse.
Pneumocystis jirovecii
Pneumocystis jirovecii is an atypical, non-culturable fungus displaying strict human host-species specificity. Formerly classified as a protozoan, DNA sequencing confirmed its fungal taxonomy within the Ascomycota.
Important
The cell membrane of Pneumocystis jirovecii contains cholesterol rather than ergosterol! Consequently, polyenes (amphotericin B) and azoles have zero therapeutic activity . Furthermore, although the cystic form contains (1,3)-beta-D-glucan in its wall, the predominant trophic form lacks glucan, rendering echinocandins clinically ineffective as monotherapy .
Clinical Features: Causes Pneumocystis pneumonia (PCP / PJP) in immunocompromised individuals: HIV with CD4 <200 cells/ μ \mu μ L, solid organ transplant recipients, hematologic malignancy patients, and those receiving prolonged high-dose corticosteroids (≥ 20 mg prednisone equivalent daily for ≥ 4 weeks). Characterized by progressive exertional dyspnea, nonproductive cough, fever, elevated serum lactate dehydrogenase (LDH), and bilateral perihilar ground-glass alveolar opacities on chest radiography.
Diagnostics: Staining of induced sputum or bronchoalveolar lavage fluid with Gomori methenamine silver (GMS) demonstrates classic crushed ping-pong ball or cup-shaped cysts. Direct fluorescent antibody (DFA) staining and real-time PCR provide high sensitivity. Elevated serum (1,3)-beta-D-glucan is highly sensitive (>90%) for PCP, aiding diagnosis when sputum collection is delayed.
Therapeutic Principles: The treatment of choice is high-dose trimethoprim-sulfamethoxazole (TMP-SMX) (15–20 mg/kg/day of the TMP component IV or orally in divided doses) for 21 days. In moderate-to-severe disease—defined by room-air arterial oxygen tension P a O 2 < 70 mmHg PaO_2 < 70\text{ mmHg} P a O 2 < 70 mmHg or alveolar-arterial oxygen gradient ( A − a ) D O 2 ≥ 35 mmHg (A-a)DO_2 \ge 35\text{ mmHg} ( A − a ) D O 2 ≥ 35 mmHg — adjunctive systemic corticosteroids (oral prednisone or IV methylprednisolone tapered over 21 days) must be initiated prior to or concurrently with antimicrobials to blunt inflammatory alveolar injury triggered by dying trophic organisms.